Evolus EOLS 深 沪
等待开盘 09-17 09:30:00 美东时间
7.89
-0.020
-0.25%
华盛通- 最 高8.09
- 今 开7.93
- 成交量 35.15万股
- 最 低 7.88
- 昨 收 7.91
- 总市值 5.21亿
- 52周最高 9.31
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.86
- 委 比 22.83%
- 总股本 6605.04万
- 历史最高 39.50
- 量 比 0.52
- 振 幅 2.65%
- 历史最低 2.85
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
AEON Biopharma announced positive results from a pilot study comparing ABP-450 to BOTOX® under thermal and oxidative stress. Both products showed comparable potency loss under thermal stress and similar oxidation patterns at methionine sites under oxidative stress. These findings provide analytical evidence supporting structural comparability and will inform AEON's planned multi-lot comparability study. The study highlights the importance of forc...
09-09 12:00
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning1...
09-01 15:59
Telix Appoints David Gill as Chair
David Gill appointed as Chair of Telix Pharmaceuticals Board, effective immediately. He joined Telix in May 2026 as a Non-Executive Director with the intention of becoming Chair. Dr. Mark Nelson, interim Chair, will continue as a Non-Executive Director. Gill brings over 35 years of experience in life sciences, financial leadership, and corporate strategy. Telix is a global radiopharmaceutical company advancing targeted theranostics for cancer tre...
08-31 22:21
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma, a biopharmaceutical company developing ABP-450 as a biosimilar to BOTOX for therapeutic use, announced that its management will host in-person investor meetings at the Lake Street Capital Markets' BIG10 Conference in New York City on September 10, 2026. ABP-450, manufactured by Daewoong Pharmaceutical, aims for full-label U.S. market entry in the $3 billion therapeutic neurotoxin market.
08-31 12:00
美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
08-25 19:56
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
AEON Biopharma appoints Dr. Paul Lee as acting Chief Regulatory Officer to lead the regulatory strategy for ABP-450, a biosimilar to BOTOX. Dr. Lee, with extensive FDA experience, will oversee interactions with the FDA and guide the development program under the 351(k) biosimilar pathway. AEON aims to achieve full-label U.S. market entry for ABP-450, targeting the $3 billion therapeutic neurotoxin market.
08-24 12:00
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON Biopharma announced progress in ABP-450's development as a BOTOX biosimilar, achieving 98% sequence coverage with 100% amino acid identity and confirming the critical C430-C454 disulfide bond. FDA feedback from an upcoming Type 2b meeting will guide future clinical studies, supporting the molecule's potential for full U.S. market entry.
08-19 12:00
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $84.084 million which beat ...
08-06 04:28
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
08-06 04:09
